that's GOOD science!

In vitro cleavage efficiency of sgRNAs correlates with functional genome editing in target cells

- **A novel *in vitro* assay to test sgRNA cleavage efficiency**
  Screen various sgRNAs to determine the most effective sgRNAs prior to delivering to your cells
- **Accurate prediction of sgRNA cleavage efficiency**
  sgRNA cleavage efficiency predicted *in vitro* correlates with *in vivo* cleavage as assessed by both a nuclease assay and functional analysis

Introduction

In CRISPR/Cas9 genome editing, targeting the Cas9 nuclease to a specific genomic locus is solely mediated by a user-defined sgRNA. Currently available web-based tools for sgRNA design will return a variety of candidate sgRNAs for a single gene target. Despite these *in silico* predictions, not every sgRNA will exhibit equivalent cleavage efficiency. Given this inconsistency, it is necessary to screen multiple sgRNAs to identify the most effective one.

Results

An *in vitro* assay to test sgRNA cleavage efficiency

The Guide-it sgRNA Screening Kit is a complete system for predicting the cleavage efficacy of sgRNAs *in vitro,* prior to use for genome editing in cells (Figure 1). With this kit, a template containing a sgRNA-target site is created by PCR; then the test sgRNA and recombinant Cas9 nuclease are added. The efficiency of Cas9-mediated cleavage can be measured by agarose gel electrophoresis.

1 Use PCR to generate a target for cleavage



2 *In vitro* cleavage of target sequence by recombinant Cas9 and synthesized sgRNA



3 Separate cleavage products on an agarose gel



Figure 1. Overview of the Guide-it sgRNA Screening Kit protocol. A PCR amplicon containing a sgRNA target site is synthesized from genomic DNA (Step 1). The PCR fragment is then combined with a candidate sgRNA and recombinant Cas9 (Step 2). The entire reaction is separated by agarose gel electrophoresis (Step 3). Since the sgRNA-target sequence is located asymmetrically within the amplicon, cleavage by the Cas9/sgRNA complex results in two bands of unequal length that can be easily distinguished on an agarose gel.

sgRNAs exhibit different cleavage efficiencies

CRISPR/Cas9 genome editing was used to disrupt the *CXCR4* locus in HeLa cells. *CXCR4* encodes a cell surface chemokine receptor that interacts with the CXCL12 chemokine and plays an important role in the immune system. In this experiment, four different sgRNAs targeting the *CXCR4* locus were tested using the Guide-it sgRNA Screening Kit. Briefly, sgRNAs targeting the *CXCR4* gene were synthesized using the Guide-it sgRNA *In Vitro* Transcription Kit. A PCR fragment containing the sgRNA target sequence was mixed with recombinant Cas9 protein and each sgRNA. The cleavage reaction was analyzed by agarose gel electrophoresis. Densitometry (Cong *et al.,* 2013) showed that sgRNA3 had the lowest cleavage efficiency (Figure 2).



Figure 2. Differences in *in vitro* cleavage efficiency as determined by the Guide-it sgRNA Screening Kit. The cleavage efficiency of four different sgRNAs targeting the *CXCR4* locus were tested. A PCR fragment containing the *CXCR4* target sequence was synthesized and mixed with Cas9 and each sgRNA. A negative control that lacked sgRNA was included for comparison (NC). Cleavage efficiency was assessed by agarose gel electrophoresis and measured using densitometry (%).

In vitro cleavage efficiency predicts *in vivo* cleavage

HeLa cells were cotransfected with plasmids encoding Cas9 and each of the four different sgRNAs tested above. The presence of mutations in the *CXCR4* locus as was assayed using the Guide-it Mutation Detection Kit. This assay uses a mismatch-specific nuclease, Guide-it Resolvase, to identify insertions or deletions in specific loci in cells treated with engineered nucleases. Mismatches were detected with high efficiency in cells treated with sgRNAs 1, 2, and 4 (Figure 3). However, cells treated with sgRNA3 exhibited a very low efficiency of mismatches, consistent with the efficiency predicted by the Guide-it sgRNA Screening Kit (Figure 2).



Figure 3. sgRNA-mediated cleavage in HeLa cells as determined by the Mutation Detection Kit. HeLa cells were co-transfected with plasmids encoding Cas9 and one of the four different sgRNAs using Xfect Transfection Reagent. Six days after transfection, cells were assayed for the presence of mutations using Guide-it Resolvase, a mismatch-specific nuclease. Cleavage fragments were present for all sgRNAs except sgRNA3, indicating low Cas9 guiding efficiency for this particular sgRNA.

CXCR4 gene disruption was also assessed by flow cytometry; since CXCR4 is a cell surface receptor, it can be detected by flow cytometry using a FITC-labeled CXCR4 antibody. Disruption in *CXCR4* expression could be detected in cells transfected with Cas9 and sgRNAs 1, 2, and 4 (Figure 4). In contrast, for cells transfected with Cas9 and sgRNA3, a much smaller proportion of the cells had disruption of *CXCR4* expression. These functional data confirm the results obtained by both the Guide-it sgRNA Screening Kit and the Guide-it Mutation Detection Kit.



Figure 4. Flow cytometric analysis detects sgRNA-mediated loss of CXCR4 function. Knockout of the *CXCR4* gene by CRISPR/Cas9 editing results in in reduced protein expression; therefore, FITC staining is inversely correlated with efficient genome editing. In this experiment, HeLa cells were cotransfected with plasmids encoding Cas9 and each of four sgRNAs, and then stained with a FITC-labeled antibody against CXCR4. The percentage (%) of the cell population that was *not* labeled with FITC is shown in blue. Cells treated with Cas9 and sgRNA3 exhibited the greatest percentage of FITC+ cells and the least efficient genome editing.

Conclusions

There is a clear correlation between *in vitro* sgRNA cleavage efficiency as predicted by the Guide-it sgRNA Screening Kit and *in vivo* sgRNA-mediated cleavage as assessed by the presence of indels and functional gene knockout (Figure 5). These results indicate that the Guide-it sgRNA Screening Kit is an ideal method for screening for ineffective sgRNAs during CRISPR/Cas9 genome editing projects.



Figure 5. The Guide-it sgRNA Screening Kit accurately predicts *in vivo* sgRNA efficacy. Cleavage efficiency was assessed by *in vitro* cleavage (Figure 2) and the Guide-it Mutation Detection Kit (Figure 3); functional knockout was assessed by flow cytometry (Figure 4, % of CXCR4− cells). There is a clear correlation between the efficiency predicted by the Guide-it sgRNA Screening Kit, the estimation of *in vivo* cleavage provided by the Mutation Detection Kit, and the level of functional knockout (via flow cytometry).

that's GOOD science!

References

Cong, L. *et al.* (2013) Multiplex genome engineering using CRISPR/Cas9 systems. *Science* **339**(6121):819–23.

Related Products

Cat. #	Product	Size	License	Quantity	Details
632636	Guide-it™ Complete sgRNA Screening System	50 Rxns		*	

The Guide-it Complete sgRNA Screening System includes everything needed for the simple production, cleanup, and evaluation of single guide RNAs (sgRNAs) for CRISPR/Cas9 studies, including PCR reagents for amplifying your genomic target and recombinant Cas9 for *in vitro* analysis of the transcribed sgRNA.

Documents	Components	Image Data

Cat. #	Product	Size	License	Quantity	Details
632638	Guide-it™ IVT RNA Clean-Up Kit	50 Rxns		*	
631443	Guide-it™ Mutation Detection Kit	100 Rxns		*	
631448	Guide-it™ Mutation Detection Kit	25 Rxns		*	
632635	Guide-it™ sgRNA In Vitro Transcription Kit	50 Rxns		*	
632639	Guide-it™ sgRNA Screening Kit	50 Rxns		*	

Add to Cart

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2018 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.